Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Return on Sales (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Return on Sales for 7 consecutive years, with 408.56% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 11957.0% year-over-year to 408.56%, compared with a TTM value of 408.56% through Dec 2025, down 11957.0%, and an annual FY2025 reading of 408.56%, down 11957.0% over the prior year.
  • Return on Sales was 408.56% for Q4 2025 at aTYR PHARMA, down from 140.76% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.77% in Q4 2022 and bottomed at 408.56% in Q4 2025.
  • Average Return on Sales over 5 years is 110.33%, with a median of 53.26% recorded in 2023.
  • The sharpest move saw Return on Sales crashed -25385bps in 2024, then skyrocketed 14882bps in 2025.
  • Year by year, Return on Sales stood at 14.77% in 2021, then surged by 95bps to 0.77% in 2022, then plummeted by -20225bps to 155.58% in 2023, then tumbled by -86bps to 289.0% in 2024, then crashed by -41bps to 408.56% in 2025.
  • Business Quant data shows Return on Sales for ATYR at 408.56% in Q4 2025, 140.76% in Q3 2025, and 289.0% in Q4 2024.